Results 91 to 100 of about 1,839,177 (303)
FEBS Letters, EarlyView.Structural and biochemical characterisations show that the planar cell polarity (PCP) protein Inturned harbours a unique PDZ‐like domain that does not bind canonical PDZ‐binding motifs (PBMs) like that of another PCP protein Vangl2. In contrast, the apical‐basal polarity protein Scribble contains four PDZ domains that bind Vangl2, but one PDZ domain ...
Stephan Wilmes +4 more
wiley +1 more source
MAIN PROBLEMS OF MOULDING OF SILUMINS. WAYS OF SOLUTION
Литьë и металлургия, 2016 The main problems of silumin’ moulding are connected with insufficient modifying of casting structure, their considerable inclination to gas porosity, difficult to remove nonmetallic inclusions and these features are shown in the article.
E. I. Marukovich, V. Yu. Stetsenko
doaj
, 1985 A swirler for a gas turbine engine combustor is disclosed for simultaneously controlling combustor flow rate, swirl angle, residence time and fuel-air ratio to provide three regimes of operation. A first regime is provided in which fuel-air ratio is less
Kelm, J. S. +3 more
core +1 more source
Tau acetylation at K331 has limited impact on tau pathology in vivo
FEBS Letters, EarlyView.We mapped tau post‐translational modifications in humanized MAPT knock‐in mice and in amyloid‐bearing double knock‐in mice. Acetylation within the repeat domain, particularly around K331, showed modest increases under amyloid pathology. To test functional relevance, we generated MAPTK331Q knock‐in mice.
Shoko Hashimoto +3 more
wiley +1 more source
NANOSTRUCTURAL PROCESSES OF MELTING AND MOULDING OF STEEL
Литьë и металлургия, 2016 It is shown that melting and molding of steel are difficult physical and chemical nanostructural processes. In them the major role is played by the centers of crystallization of dendrites of austenite, austenite nanocrystals, the dissolved and adsorbed ...
V. Yu. Stetsenko
doaj
BMC Musculoskeletal Disorders, 2005 Background Pharmacological treatment for osteoarthritis (OA) can be divided into two groups: symptom-modifying drugs and disease-modifying drugs. Symptom-modifying drugs are currently the prescription of choice for patients with OA, as disease-modifying ...
Ginai Abida Z +7 more
doaj +1 more source
Structural insights into an engineered feruloyl esterase with improved MHET degrading properties
FEBS Letters, EarlyView.A feruloyl esterase was engineered to mimic key features of MHETase, enhancing the degradation of PET oligomers. Structural and computational analysis reveal how a point mutation stabilizes the active site and reshapes the binding cleft, expading substrate scope.
Panagiota Karampa +5 more
wiley +1 more source
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019 Background Tuberculosis screening is recommended in multiple sclerosis patients starting certain disease-modifying therapies. Disease-modifying therapies may affect interferon-gamma release assay results.
Laura E Baldassari +7 more
doaj +1 more source
Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system
FEBS Letters, EarlyView.Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley +1 more source
Disease-modifying treatments for Alzheimer’s disease
Therapeutic Advances in Neurological Disorders, 2011 The first drugs developed for Alzheimer’s disease (AD), acetylcholinesterase inhibitors (AChEI), increase acetylcholine levels, previously demonstrated to be reduced in AD. To date, four AChEI are approved for the treatment of mild-to-moderate AD.
Daniela Galimberti, Elio Scarpini
doaj +1 more source